Today would have likely felt like Day 3 of the market siege, but thankfully the master of the universe came to a key firm's rescue. The bad news is that the stock markets were mixed all day and the key index levels didn't gain at the end of the day. The good news is that there was no systematic free fall. Bernanke changed his tone marginally to convey a better bailout message, and Paulson was more on target today in conveying the need and lack of outright costs to the system. Things are so bad that the Presidential campaigns are being put on hold temporarily.

Here are today's unofficial closing bell levels:
DJIA 10,825.17 -29 -0.275%
NASDAQ 2,155.68 +2.35 +0.11%
S&P500 1,185.89 -2.23 -0.19%
10YR T-Note 3.771% (-0.07%)
Top Analyst Upgrades
Top Analyst Downgrades
52-Week Low Club

Goldman Sachs Group Inc. (NYSE: GS) was the real stabilizer today despite what the overall index levels closed at. It raised $5 billion in a stock sale and received a $5 billion investment from Warren Buffett. Shares were up almost 6% at $132.20 right before the close.

Sequenom (NASDAQ: SQNM) makes the MassARRAY system, a nucleic acid analysis platform that identifies and quantifies genetic target materials. The system is composed of electronic analysis equipment, related software and various consumables. It is used in biomedical research, livestock testing, oncology diagnoses, molecular medicine, noninvasive prenatal testing, and infectious disease identification. Customers include clinical research laboratories, biotechnology concerns, and universities.

The company surprised the Street last week, when it announced a successful trial of its prenatal test used to detect Down-syndrome in a mother's blood. In blinded studies involving 200 clinical samples, Sequenom's proprietary test identified all Down-syndrome samples with no false positives. The company pointed out that current testing options have a detection rate of 70-90%, with false-positive rates as high as 5%. Management said it will start a study of several thousand samples in the fourth quarter, in preparation for a U.S. launch of the test in the first half of 2009.

This was quite a week in biotechnology. You had a major premium buyout and had much data come out from the American Society of Clinical Oncology (ASCO) and others. This is far from all of the movers, but it is a brief summary of the major gainers from BioHealthInvestor.com showing how large some moves were in biotechnology this week.

Acorda Therapeutics Inc. (NASDAQ: ACOR) had a great week after it announced positive data from a second Phase III study of its Fampridine-SR for patients' walking abilities who suffer from multiple sclerosis (MS). FULL DETAILS

Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) was a strange stock this week. The company reported great news but shares slid before the market figured out it had misinterpreted news in the company. INITIAL DETAILS

Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) saw a surge after it reached its primary endpoint in Phase III trial of Denufosol for Cystic Fibrosis. FULL DETAILS

MOST NOTEWORTHY: AU Optronics, General Steel and Sequenom were today's noteworthy initiations:

• Jefferies initiated AU Optronics (NYSE: AUO) with a Buy rating and $25 target and believes LCD trends will be healthy in 2008 despite a soft economy.
  
• General Steel (NYSE: GSI) shares were started at Merriman with a Buy rating, as the firm believes strong demand for steel in China should last for years and finds the valuation attractive at current levels.
  
• Cantor believes Sequenom (NASDAQ: SQNM) is positioned to establish sustainable market leadership as a provider of genome analytical products and molecular diagnostics. Shares were assumed with a Buy rating and $12 target.

OTHER INITIATIONS:

• UBS initiated Altria Group (NYSE: MO) with a Buy rating and $30 target.
  
• Canaccord Adams assumed Drugstore.com (NASDAQ: DSCM) with a Buy rating and $3.50 target.
  
• Goldman Sachs initiated DirecTV (NASDAQ: DTV) with a Buy rating and $30 target.

MOST NOTEWORTHY: Big 5 Sporting Goods (BGFV), Nutrition 21 (NXXI), Sonic Solutions (SNIC), AeroGrow (AERO) and Sequenom (SQNM) were today's noteworthy initiations:

• Nollenberger believes Big 5 Sporting Goods' (NASDAQ: BGFV) shares are fairly valued and would likely get more constructive near the $20 level and initiated shares with a Neutral rating.

• ThinkEquity said Nutrition 21 (NASDAQ: NXXI) has a number of clinically proven nutritional supplements that target the rapidly growing obesity and diabetes markets, and initiated shares with a Buy rating.

• SMH Capital initiated shares of Sonic Solutions (NASDQ: SNIC) with a Buy rating, on the belief that shares have been oversold.

• ThinkEquity is positive on AeroGrow's (NASDAQ: AERO) proprietary aeroponic technology and recurring revenue model and initiated shares with a Buy rating.

• Leerink Swann started shares of Sequenom (NASDAQ: SQNM) with an Outperform rating as MEDACorp researchers are positive regarding the company's MassARRAY system for genetic analysis, which is well-positioned for growth in follow-on SNP fine-mapping studies; Leerink anticipates in 2008, the company will launch iPLEX 3, which is currently in development, and reduce the cost of acquiring fine-mapping SNP data...

OTHER INITIATIONS:

• Dover (NYSE: DOV) was initiated at Morgan Stanley with an Overweight rating.

• Merrill started Akamai (NASDAQ: AKAM) with a Neutral rating.

• Pacific Crest started Wipro Ltd (NYSE: WIT) with a Sector perform.

• Susquehanna initiated Herman Miller (NASDAQ: MLHR) with a Positive rating.

• RBC Capital initiated Warren Resources (NASDAQ: WRES) with an Outperform rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).